Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Something went south in Africa for sure timeline was start in May, had been working with officials, already there setting up and then oh we need insurance and the start is July or August now. That is why I think it was asked for by the officials because they sensed that ENZC needs this trial to happen, so they had the bargaining chip and not ENZC. Now the hard part is getting exactly what to be covered by insurance. The people involved already are infected so insurance can't cover that part of the issue , so is it going to cover any issues arising from ENZC that brings on a different issue other than what is currently present. We know from other studies and test that it has proven safe. Who knows but ENZC what is going on, we are all just trying to put piece of the puzzle together at this point and everytime we are almost think we have the puzzle figured out we get a 1000 more pieces add to the mix.
Jim what is your take and are you still on that 15 month plan or will you be holding a bit longer?
GLTA
I hear ya , I really dont see anything being released as major news or deals until late Sept Oct maybe even Nov. , They haven't started in Africa according to their own PR due to insurance issues. That is a new one on me, haven't seen a trial needing insurance usually just the opposite you sign waivers over issues occuring from it. Not saying it hasnt ever been asked for or issued. Africa could have asked for it since they knew ENZC needs to do a trial, ENZC could have offered it, but you would think they would have already set it up ahead of time and had it ready to go as a bargaining chip. That kind of makes you think it was Africa officials that asked for it. Either way a few more months is not a big thing if you are long and have confidence in the company. Hoping I am dead wrong about major news timeline and it is dropped earlier than my thinking.The patent timeline puts us all most in August, Regeneron stated late in the year 3rd Qrt starting trials, and Africa results at the midway mark is at its best Sept, that is why I have my own timeline in mind. GLTA
Come on now MP you know a few just made beer money on the Low to High just now Just a little Friday sarcasm. GLTA
Wishing you a Speedy recovery . GLTA
I for one and many others have had orders go unfilled and alot less than a million share you are buying. So something is going on or are you just that lucky all the time? show the magic and pull off a 750k to 1 million buy today
I think this is what we are thinking we read, go to claims that was where I was recalling the 38 steps ect.. GLTA
DRHUMI
Re: None
Thursday, March 23, 2023 12:25:54 PM
Post#
172178
of 179649
The written opinion is brutal on the patent application. I have no idea what "opinion" means concerning the possible issuance of the patent... Is it literally an opinion by a bunch of geeks that can't influence the decision?
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2023043880&_cid=P21-LFL63P-93947-1
BonnieMac
Re: DRHUMI post# 172189
Thursday, March 23, 2023 1:20:42 PM
Post#
172191
of 179649
You have to go back to $ENZC's PR's in the past to find the Announcement about its original WIPO Application. You can find it on our Co. Website. The PR stated that ENZC had been given preliminary Approval for its HIV Patent as being novel and inventive. The waiting/review period for Approval is 18 months, which is up now & WIPO granted Approval for ENZC's Patent Application today.
BonnieMac
Re: DRHUMI post# 172178
Thursday, March 23, 2023 12:55:28 PM
Post#
172186
of 179649
WIPO website stated today, Mar. 23, 2023:
"Abstract
(EN) Described are novel HIV-binding peptides and methods of using them for treating or preventing HIV infection and/or the development of AIDS."
The 18-month waiting period is up now, so approval that $ENZCs patent is "novel" has just been given.
See Godfather's Tweet posted about 1 hr ago today, Mar. 23, 2023:
This is fabulous News!
Valuator2
Member Level
Re: bld1 post# 172319
Saturday, March 25, 2023 3:57:51 PM
Post#
172322
of 179645
I'm not a patent attorney either and am a little confused about what the next step is for this particular application. The application appears to still be active. Maybe somebody else can clarify.
So, isn't the report part of the application process: Patenting agency objects, claims some reasons why it shouldn't be granted, applicant's patent lawyers rebut objections or amend the claims, further assessment is made and maybe the patent is granted.
Are we still in that stage with this particular patent or are the novel and industrial application determinations enough to move forward?
The objection expressed in the report was that a new inventive step wasn't identified in the application's claims because essentially, the effect of Pepsin was already known, but I think I recall that the prior patented art quoted in the report included Cotropia's original patent.
In regard to unity of invention, that sounded like the reviewer claimed there were more than one patent potentials within the claim as opposed to just one. So, is bifurcation necessary or is it permissible as is?
COLLEGE STATION, TX / ACCESSWIRE / July 28, 2022 / Enzolytics, Inc. (OTC PINK:ENZC) ("ENZC" or the "Company"). In the first Official Action on the Company's International Patent Application covering its discovery and exclusive claim to conserved antigens and epitopes of the HIV virus, the PCT International Search Report concluded that inventions claimed therein are novel and inventive and thus will expectedly be issued in final international patents.
The Company's International Patent application covers (1) the discovered highly conserved antigens and epitopes (sites) on the HIV virus, (2) antibodies that bind to the disclosed antigens and epitopes, (3) vaccines based on the antigens, (4) methods of treating, preventing, or reducing the risks of HIV infection with the antigens or binding proteins, and (5) methods and kits for detecting or diagnosing infection by HIV using the antigens or binding proteins.
The claimed virus sites were discovered by the Company through computer analysis (Artificial Intelligence (AI)), wherein tens of thousands of HIV isolates were curated to identify these critical, conserved, immutable epitopes on the virus. These sites are now claimed as patentable based on their novel specificity and the finding that they are conserved on the HIV virus. This is significant in that by producing antibodies that attack these conserved, immutable sites, the virus can be neutralized rather than be unaffected as a result of virus mutation that avoids the therapeutic.
The Company is producing fully human monoclonal antibodies against these claimed sites. These discoveries have now been confirmed by the International Patent Office to be novel and inventive, capable of being patented and claimed exclusively for a 20-year term in every member country under the Patent Cooperation Treat in which the Company pursues these claims.
The Company expects the same favorable results in the PCT Patent Office for its pending applications covering epitopes (binding sites) on the CoronaVirus (covering all variants), on the Monkeypox Virus, and on numerous animal viruses, namely Feline Leukemia Virus (FeLV), Feline Immunodeficiency Virus (FIV), Elephant Endotheliotropic Virus, Equine Infectious Anemia, and Koala Retrovirus. The Company fully expects the issuance of multiple international patents covering these discoveries.
The Company's PCT applications also cover the identification of highly conserved antigens and epitopes of these viruses that can be used in the production of treating antibodies, and the production of vaccines for treating, preventing, or reducing the risks of infections caused by these viruses.
The patents also cover the discovery of using these identified antigens and epitopes as targets for detecting and diagnosing viral infection. This is a significant development since these patents cover not only treatment and prevention but also targets for detection and diagnosis of infections for all viruses being pursued by Enzolytics.
I recall reading that one had a few sections denied as non inventive, on that same issue they could go back and provide better write up and procedures to be looked at again. Another if I recall ask for more information on the procedure. It was like 38 things within the patent. Again going on recall, that info is out there to verify. GLTA
https://finance.yahoo.com/news/enzolytics-announces-discovery-patenting-8-130000732.html
Enzolytics has filed two patents for the treatment of Multiple Sclerosis 12. The first patent was filed on December 9, 2020, and is titled “NUCLEAR PROTEINS ISOLATED FROM MAMALIAN SPINAL CORD (SCNP) IMMUNE FACTOR” 1. The second patent application was filed on January 19, 2021, and is titled “Nuclear Proteins Isolated from Mammalian Spinal Cord Immune Factor - Pharmaceutical Composition for Treatment” 2.
https://www.accesswire.com/624750/Enzolytics-Inc-Receives-Official-Filing-Receipt-for-Multiple-Sclerosis-Patent-Application
https://finance.yahoo.com/news/enzolytics-announces-international-patent-office-103000840.html
https://www.digitaljournal.com/pr/enzolytics-announces-its-new-technology-for-entry-into-the-in-vitro-diagnostics-market
Usually it takes about 2 years so the window is now here , so if any will be granted it will be in the upcoming months
Keep in mind Regeneron timeline is most of the time very conservative, and they come in well before the date they say. Maybe ENZC & Regeneron are head of their timelines and we see something sooner than Oct or Nov . Hoping for the best but either way a few months to hold isn't going to hurt. GLTA
Hope so at this point GLTA
Unless they are part of this group , I don't think it is enzolytics. the developers of CAB-LA, ViiV Healthcare, and the United Nations-backed Medicine Patent Pool (MPP), They mention that (A branded version does exist, and in the USA just one injection costs $3,500. )
Enzolytics needs to get things going in Africa ,
interesting read
https://www.pressenza.com/2023/05/south-africa-begins-its-own-production-of-groundbreaking-hiv-prevention-drug-to-make-it-affordable-within-the-continent/
Where are the cheerleaders , price rose a penny over the past 2 weeks. Bought low and sold high again?
Do you think the longs all decided to sell off 158 million shares in the .04-.05 range after holding this long?
Maybe they can get in on this as the year goes on , they most likely have ran A/I and know what to go after. GLTA
https://www.msn.com/en-us/health/health-news/fda-advisers-consider-changing-covid-vaccine-to-target-latest-omicron-strain/ar-AA1cAYN2?ocid=hpmsn&cvid=753dbff81a2b4419b061b592c3be3ee3&ei=15
Now it has been 3 months, no up listing news, no investment funding, no buyout ? Where is Koos?
Not sure if this is the same BN Holding trust
Business Overview
Business Registration Australian Business Register (ABR)
Australian Business Number (ABN) 31 765 133 190
ABN Status Active (2018-09-10)
Entity Name The Trustee for BN Holdings Trust
Business Address QLD 4313
Australia
Entity Type Discretionary Investment Trust (DIT)
Main Entity - NonIndividual Name The Trustee for BN Holdings Trust
Last Update Date 2018-09-10
If that is the case , we sit and wait again. If they are looking for results is understandable but they surely have seen the years of testing confirmation from 5 different reviews.
With the date being pushed back that puts results outside the timeline for Saga to complete a deal. If I was the buyers ( investors) I would like to see results before finalizing a 250m deal or whatever it ends up to be. I know with results the price would go up which would be a good thing for investors.
Here is a question why doesn't Samsung buy the two companies for this low bargain price?
Maybe we will have a great X-MAS with the current timeline.
Jim that puts you on the fence with your timeline or are you going to do an extention?
GLTA
Yes I understand that, I would want to be involved in the deal when it is two of the companies I own and with the track record of SAGA I would be at the table.
I hear you , they were the one saying first week in June , now by the sound of this news it is 2 or 3 months away. I agree with another poster that the sale of shares is for funding no doubt. I just don't understand why Samsung hasn't picked up a few million dollar that may be needed for funding for Enzolytics. GLTA
This too a little strange you are selling two companies and you are not part of negotiations ?
While there is no deadline for completion of the business combination agreement between ENZC and SAGA both parties will be working to complete the transaction as quickly as possible upon the completion of the regulatory filings and negotiations between the existing sponsor and BN Holdings Trust. The Company is not a party to the negotiations or filings but is being kept apprised of the progress being made.
So by the statement , it seems alittle confusing this week and then it says July August ?
The final protocol for the administration of the ITV-1 immunotherapy treatment under the supervision of Neuro Pharma Ltd - Rwanda, to be dispensed to volunteers under a fast-track protocol at HEAL Africa Hospitals, GOMA, PRC and Panzi Hospital, Bukavu, DRC, is expected to be completed this week. The impact of the treatment on the HIV/AIDS virus present in the volunteers will be reported after the 17-week cycle is complete. The next step for VIRO is to acquire and fund the insurance premiums for the volunteers. VIRO expects ITV-1 to be dispensed under the trial in late July / early August 2023.
It would be great to have the WHO heads be in attendants when the first shot would be given. Perfect photo op to take advantage of for all parts GLTA
Hey Mutat is that the Kona one I saw filed two days ago and again today
https://www.docketbird.com/court-cases/Enzolytics-Inc-v-Kona-Concepts-Inc/ded-1:2021-cv-01600?utm_source=frozen_email&utm_medium=email&utm_campaign=np_public_user_following&utm_content=following&db_uid=c83c9bb9-0982-437a-8c42-479d243c6538
Correct it did say 1st week of June , hopefully they will get this show on the road. Along time coming. Here is a good read to recall everything they are working on . I know it is a year old so we should be hearing about some of this since it is a year old. GLTA
https://www.nasdaq.com/press-release/enzolytics-inc.-reports-progress-and-future-plans-2022-04-25
Hard to say , anytime news is put out we go down instead of up. Hopefully the news is worded in a way that will change the pattern. Volume of 18m helped today usually when enzc is in the .04's we trade around 4-6m . Current time there is around 2-4 a.m. so hopefully we have news in the a.m. EST our time before markets open. GLTA
If they follow thru, we should have news tomorrow that they have started the jab. GLTA
Very interesting read, SAGA filing from a few days ago. GLTA
https://last10k.com/sec-filings/saga/0001493152-23-018432.htm
I agree with you , something is going on behind the screen. I am sure CC looked at SAGA especially when they pulled out of two deals in the last year. Funny how Oct is deadlines with NASDAQ for them , ENZC timeline falls in Oct. Extention date for the month has come and gone with no updates. Holiday weekend so they probably won't post anything tomorrow. Maybe news or updates comes out Tuesday heading into June and the jab starting on the 1st. Very interesting times we are in. GLTA
Keep in mind SAGA has alot to be cleaning up themselves. GLTAA
https://www.nasdaq.com/press-release/sagaliam-acquisition-corp.-announces-receipt-of-nasdaq-listing-delinquency-letter
ENZC has sued Kona because Kona has sued ENZC twice in Texas state and Texas federal courts and keeps harassing ENZC over a $75,000 promissory note that ENZC was not a party to. ENZC claims Eco-Petroleum was a party to the note and the subsequent entity changes means “ENZC Sub” may owe previous debts, not ENZC.
It would be great to see the end of this case soon too. GLTA
Court Cases Federal Cases Civil Cases District of Delaware 2021 2021-cv-01500 through 2021-cv-01999 Enzolytics, Inc. v. Kona Concepts, Inc.
Enzolytics, Inc. v. Kona Concepts, Inc.
Court Docket Sheet
District of Delaware
1:2021-cv-01600 (ded)
05/23/2023Motion Hearing (Text entry; no document attached.)
6105/16/2023Order
6005/16/2023Notice of Appearance
5905/15/2023Letter
5804/25/2023Notice of Service
5704/18/2023Affidavit of Service
04/12/2023Deficiency re Courtesy Copies (SRF cases) (Text entry; no document attached.)
5604/11/2023Affidavit of Service
5504/11/2023Affidavit of Service
04/10/2023Oral Order (Text entry; no document attached.)
04/10/2023~Util - Set Hearings (Text entry; no document attached.)
5304/06/2023Subpoena
5204/06/2023Request for Oral Argument
04/05/2023Order Referring Motion (Text entry; no document attached.)
5004/04/2023Brief - Reply
4904/03/2023Notice of Service
4803/30/2023Notice - Other
4703/28/2023Brief - Answering Brief in Opposition
4603/24/2023Notice of Service
4503/14/2023Brief - Opening Brief in Support
4403/14/2023Dismiss/Other
03/09/2023~Util - Set/Reset Answer Deadline (Text entry; no document attached.)
03/09/2023SO ORDERED (Text entry; no document attached.)
4303/09/2023Stipulation to EXTEND Time
4203/03/2023Notice of Service
4102/28/2023ORDER: The Report and Recommendation (D.I. 39) is ADOPTED. Plaintiffs motion to dismiss (D.I. 27) is GRANTED, and Defendants request for leave to amend its counterclaims (D.I. 30 at 9) is GRANTED. Signed by Judge Richard G. Andrews on 2/28/2023.
4002/27/2023Counterclaim
3902/06/2023REPORT AND RECOMMENDATIONS- re 27 MOTION to Dismiss Amended Counterclaim. Please note that when filing Objections pursuant to Federal Rule of Civil Procedure 72(b)(2), briefing consists solely of the Objections (no longer than ten (10) pages) and the Response to the Objections (no longer than ten (10) pages). No further briefing shall be permitted with respect to objections without leave of the Court. Objections to R&R due by 2/21/2023. Signed by Judge Sherry R. Fallon on 2/6/2023.
3802/02/2023Disclosure Statement - Rule 7.1
02/01/2023Deficiency Notice - No 7.1 Statement Filed (Text entry; no document attached.)
3701/23/2023Order
3601/23/2023Letter
3509/23/2022NOTICE OF SERVICE of Responses to Interrogatories and Request for Production of Documents of Cimarron Kona Concepts, Inc. filed by Enzolytics, Inc.
3408/10/2022NOTICE OF SERVICE of Defendant/Counterclaim Plaintiff Kona Concept Inc.'s First Set of Interrogatories and First Set of Requests for Production of Documents re [22] Scheduling Order, filed by Kona Concepts, Inc.
07/20/2022SECOND REQUEST: Per Magistrate Judge Fallon's Standing Order Regarding Courtesy Copies, which requires two (2) courtesy copies of all briefs and two (2) copies of any other document filed in support of any briefs (i.e., appendices, exhibits, declarations, affidavits etc.), please submit to the Clerk's Office two copies of D.I. numbers [27] and [28] in an envelope addressed to Judge Fallon's chambers. (Text entry; no document attached.)
07/18/2022REQUEST: Per Magistrate Judge Fallon's Standing Order Regarding Courtesy Copies, which requires two (2) courtesy copies of all briefs and two (2) copies of any other document filed in support of any briefs (i.e., appendices, exhibits, declarations, affidavits etc.), please submit to the Clerk's Office two copies of D.I. numbers [27], [28], [30] and [32]. (Text entry; no document attached.)
3307/15/2022ORAL ORDER: The Motion to Dismiss Amended Counterclaim (D.I. [27]) is now REFERRED to Magistrate Judge Sherry R. Fallon. Ordered by Judge Richard G. Andrews on 7/15/2022. Motions referred to Sherry R. Fallon.
3207/01/2022REPLY BRIEF re [27] MOTION to Dismiss Amended Counterclaim filed by Enzolytics, Inc.
06/16/2022SO ORDERED, re [31] STIPULATION and Proposed Order (*Reset Briefing Schedule: re [31] STIPULATION and Proposed Order. Reply Brief due 7/1/2022). Signed by Judge Richard G. Andrews on 7/1/2022. (Text entry; no document attached.)
3106/15/2022STIPULATION TO EXTEND TIME for Plaintiff to move, answer or otherwise respond in response to the Answering Brief in Opposition to Plaintiff/Counterclaim Defendant Enzolytics, Inc.s Motion to Dismiss filed by Kona Concepts, Inc. to 07/01/22 - filed by Enzolytics, Inc.
3006/14/2022ANSWERING BRIEF in Opposition re [27] MOTION to Dismiss Amended Counterclaim filed by Kona Concepts, Inc.
05/18/2022SO ORDERED, re [29] STIPULATION and Proposed Order (*Reset Briefing Schedule: re [27] MOTION to Dismiss Amended Counterclaim. Answering Brief due 6/14/2022). Signed by Judge Richard G. Andrews on 5/18/2022. (Text entry; no document attached.)
2905/18/2022STIPULATION TO EXTEND TIME to file an Answering Brief/Response to Plaintiff Enzolytics, Inc.s Motion to Dismiss Amended Counterclaim to June 14, 2022 - filed by Kona Concepts, Inc.
2805/06/2022OPENING BRIEF in Support re [27] MOTION to Dismiss Amended Counterclaim filed by Enzolytics, Inc.Answering Brief/Response due date per Local Rules is 5/20/2022.
05/06/2022CORRECTING ENTRY: The brief filed as an attachment to the motion at D.I. [27] has been removed. Motions and briefs are to be filed independent of each other. Counsel is directed to refile the brief accordingly. (Text entry; no document attached.)
2705/06/2022Dismiss/Other
2604/19/2022FIRST AMENDED COUNTERCLAIM to [5] Amended Complaint, against Enzolytics, Inc., by Kona Concepts, Inc.
04/19/2022CORRECTING ENTRY: The pdfs for the attachments at D.I. 24 have been replaced with amended versions. The captions on the filings have been corrected. The NEF for D.I. [24] has been regenerated. (Text entry; no document attached.)
2504/18/2022SO ORDERED Granting [24] Stipulation and Proposed Order for Modification and Filing of First Amended Counterclaim. Signed by Judge Richard G. Andrews on 4/18/2022.
2404/14/2022STIPULATION for Modification of Docket Entry No. 13 and Filing of First Amended Counterclaim re [13] Answer to Amended Complaint, Counterclaim by Kona Concepts, Inc.
2 Attachments ?
2304/05/2022ORAL ORDER: The Rule 16(b) Conference scheduled for 4/7/2022, is CANCELED. Ordered by Judge Richard G. Andrews on 4/5/2022.
2204/05/2022SCHEDULING ORDER: Joinder of Parties due by 5/31/2022. Amended Pleadings due by 5/31/2022. Fact Discovery completed by 4/28/2023. Dispositive Motions due by 11/17/2023. A Pretrial Conference is set for 3/15/2024, at 10:00 AM in Courtroom 6A. A 3 day Bench Trial is set to start 4/1/2024, at 9:30 AM in Courtroom 6A (see Order for further details). Signed by Judge Richard G. Andrews on 4/5/2022.
04/05/2022SO ORDERED, re [21] STIPULATION and Order (Reset Answer Deadlines: Enzolytics, Inc. answer due 4/15/2022). Signed by Judge Richard G. Andrews on 4/5/2022. (Text entry; no document attached.)
2104/05/2022STIPULATION TO EXTEND TIME for Plaintiff to move, answer or otherwise respond in response to Counterclaim filed by Defendant to 04/15/2022 - filed by Enzolytics, Inc.
2004/05/2022Proposed Pretrial Order Scheduling Order by Enzolytics, Inc.
03/23/2022SO ORDERED, re [19] STIPULATION TO EXTEND TIME to move, answer or otherwise respond to Counterclaim (*Reset Answer Deadlines: Enzolytics, Inc. answer due 4/8/2022). Signed by Judge Richard G. Andrews on 3/23/2022. (Text entry; no document attached.)
1903/23/2022STIPULATION TO EXTEND TIME for Plaintiff to move, answer or otherwise respond in response to Counterclaim filed by Defendant to 04/08/2022 - filed by Enzolytics, Inc.
1803/07/2022Order Setting Rule 16(b) Telephone Conference: A Scheduling Conference is set for 4/7/2022, at 2:00 PM before Judge Richard G. Andrews (see Order for further details). Signed by Judge Richard G. Andrews on 3/7/2022.
03/07/2022Pro Hac Vice Attorney John J. Muldoon, III for Kona Concepts, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (Text entry; no document attached.)
03/07/2022Remark: The Answer filed at D.I. [13] has been unsealed per the authority at D.I. [17]. (Text entry; no document attached.)
1703/07/2022ORAL ORDER: The Motion for Leave to File Under Seal (D.I. [15]) is DENIED. Ordered by Judge Richard G. Andrews on 3/7/2022.
1603/04/2022EXHIBIT re [13] Answer to Amended Complaint, Counterclaim by Kona Concepts, Inc.
03/04/2022CORRECTING ENTRY: The exhibit filed at D.I. 14 has been removed from the docket as the filing was incompletely formatted. The filing lacked a proper captioned cover page with a title for what the filing contained. Counsel is to refile the exhibit accordingly. (Text entry; no document attached.)
1503/04/2022MOTION to Seal Document: [13] Answer to Amended Complaint, Counterclaim - filed by Kona Concepts, Inc.
2 Attachments ?
1303/04/2022[SEALED] ANSWER to Amended Complaint, re: [5] Amended Complaint, Affirmative Defenses and, COUNTERCLAIM against Enzolytics, Inc. by Kona Concepts, Inc. (Attachments: # (1) Certificate of Service)
03/01/2022SO ORDERED, re [11] STIPULATION and Order (*Reset Answer Deadlines: Kona Concepts, Inc. answer due 3/4/2022). Signed by Judge Richard G. Andrews on 3/1/2022. (Text entry; no document attached.)
03/01/2022SO ORDERED, re [12] MOTION for Pro Hac Vice Appearance of Attorney John J. Muldoon, III, filed by Kona Concepts, Inc. Signed by Judge Richard G. Andrews on 3/1/2022. (Text entry; no document attached.)
1203/01/2022MOTION for Pro Hac Vice Appearance of Attorney John J. Muldoon, III - filed by Kona Concepts, Inc.
1103/01/2022STIPULATION TO EXTEND TIME for Defendant to Respond to Complaint to March 4, 2022 - filed by Kona Concepts, Inc.
1003/01/2022NOTICE of Appearance by Kaan Ekiner on behalf of Kona Concepts, Inc.
901/25/2022ORAL ORDER: The request to extend the answer deadline to March 1, 2022 (D.I.[8]) is GRANTED. Ordered by Judge Richard G. Andrews on 1/25/2022.
801/25/2022Letter to Judge Richard Andrews from Antranig Garibian regarding Updated Status Letter.
701/24/2022Letter to Judge Richard Andrews from Antranig Garibian regarding Status Letter.
601/21/2022ORAL ORDER: An answer was due to be filed on 1/17/2022 (see D.I. [4]), and to date none has been filed. status letter is now due no later than 3 days from the entry of this Order. Ordered by Judge Richard G. Andrews on 1/21/2022.
512/06/2021AMENDED COMPLAINT against Kona Concepts, Inc.- filed by Enzolytics, Inc.
411/18/2021WAIVER OF SERVICE returned executed by Enzolytics, Inc.: For Kona Concepts, Inc. waiver sent on 11/18/2021, answer due 1/17/2022.
11/17/2021Case Assigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. Associated Cases: 1:21-cv-01599-UNA, 1:21-cv-01600-UNA (Text entry; no document attached.)
11/12/2021No Summons Issued. (Text entry; no document attached.)
311/12/2021Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Enzolytics, Inc.
211/12/2021Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction.
111/12/2021COMPLAINT filed with Jury Demand against Kona Concepts, Inc. - Magistrate Consent Notice to Pltf. (Filing fee $ 402, receipt number ADEDC-3741881.) - filed by Enzolytics, Inc.
1 Attachment ?
Interested in this case?
Get Instant Updates
Would you like this case removed from DocketBird? Request removal.
Other 2021 Cases in the District of Delaware:
Ellington v. Kane et al (ded-1:2021-cv-01404)
Emerson Process Management Regulator Technologies, Inc. v. Pietro Fiorentini (USA), Inc. (ded-1:2021-cv-01488)
Enevoldsen v. State of Delaware et al (ded-1:2021-cv-01684)
Enic v. Fritzlen (ded-1:2021-cv-01462)
Enzolytics, Inc. v. Cimarron Capital, Ltd. (ded-1:2021-cv-01599)
Errant Gene Therapeutics, LLC v. Bluebird Bio, Inc. (ded-1:2021-cv-01478)
Escalera v. Robert May, Warden et al. et al (ded-1:2021-cv-01331)
Etak Systems, LLC v. B+T Group Holdings, Inc. (ded-1:2021-cv-01532)
Evans v. Cantor Insurance Group, LP. (ded-1:2021-cv-01618)
Extang Corporation et al v. Truck Accessories Group, LLC (ded-1:2021-cv-01325)
Could be one of the NDA in place.
Nice find , Can you image if the WHO authorizes anything made by ENZC to combat the wave if it does happen. That would be the news that would have impact .GLTA
I agree with you I didn't see this deal being done on time.
About Clone 3 , I think they are using the technology learned from Clone 3 and are working together to create a new drug that is why no IND or true creator credit yet Just a guess , time will tell on that . GLTA